Esophagogastric Junction Adenocarcinoma

• CLINICAL_TRIALS research · 2026-04-21
  Clinical Trial Update: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas [Phase 3]

  Phase 3 clinical trial investigating a combination of an immune checkpoint inhibitor for locally advanced or metastatic MSI/dMMR esogastric …

• CLINICAL_TRIALS research · 2026-04-21
  Clinical Trial Update: Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ [Phase 2]

  Sintilimab plus chemotherapy is being evaluated as adjuvant therapy in a Phase 2 study for gastric adenocarcinoma and esophagogastric juncti…

• CLINICAL_TRIALS research · 2026-03-25
  Clinical Trial Update: Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy [NA]

  This is a single-arm Phase II study assessing the safety and efficacy of Retlirafusp Alfa in combination with chemotherapy as perioperative …

• CLINICAL_TRIALS research · 2026-03-03
  Clinical Trial Update: Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

  Phase 2 neoadjuvant trial evaluating anti-PD-1 therapy plus thymalfasin and the SOX regimen (S-1 + oxaliplatin) in clinical stage III gastri…

• CLINICAL_TRIALS research · 2025-12-19
  Clinical Trial Update: A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma [Phase 1]

  Phase Ib trial evaluating the safety and activity of neoadjuvant tislelizumab plus the FLOT chemotherapy regimen in patients with resectable…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-12-03
  Clinical Trial Update: AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)

  A ClinicalTrials.gov entry for the AROMA2 study examines whether volatile biomarker profiles can augment assessment of esophagogastric cance…

• CLINICAL_TRIALS research · 2025-08-20
  Clinical Trial Update: Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer [Phase 4]

  A Phase 4 clinical trial update evaluating adjuvant chemotherapy with or without immunotherapy after radical surgery for resectable gastric …

• CLINICAL_TRIALS research · 2025-06-12
  Clinical Trial Update: Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma [Phase 2]

  A Phase 2 trial evaluating neoadjuvant immunochemotherapy for locally advanced Esophagogastric Junction adenocarcinoma is currently recruiti…

• CLINICAL_TRIALS research · 2025-06-10
  Clinical Trial Update: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial [Phase 2]

  A Phase 2 maintenance therapy trial for oesophago-gastric cancer is active but not recruiting, focusing on esophageal, gastroesophageal junc…

• CLINICAL_TRIALS research · 2025-05-23
  Clinical Trial Update: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients [Phase 2]

  Ongoing phase 2 trial of savolitinib for gastric cancer and esophagogastric junction adenocarcinoma; the study is currently not recruiting.

• CLINICAL_TRIALS research · 2024-10-16
  Clinical Trial Update: Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma [NA]

  An ongoing clinical trial is evaluating right versus left thoracic surgical approaches for Siewert Type II gastroesophageal junction adenoca…

• CLINICAL_TRIALS research · 2024-08-28
  Clinical Trial Update: Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma [Phase 3]

  A Phase 3 trial evaluating nimotuzumab in combination with paclitaxel for recurrent/metastatic gastric cancer or esophagogastric junction ad…

• CLINICAL_TRIALS research · 2024-07-01
  Clinical Trial Update: Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study [Phase 2]

  Phase 2 feasibility study evaluating perioperative immunotherapy with adebrelimab combined with XELOX (capecitabine and oxaliplatin) for res…